Investor Buys Six Stocks Amid Market Volatility in 2025

Market volatility, driven by tariff-related uncertainty, presented a significant opportunity for long-term investors in mid-2025. This period saw the S&P 500 and Nasdaq Composite experience substantial declines, creating favorable entry points into high-quality stocks.

Investment Strategy in a Volatile Market

The investor’s approach centered on capitalizing on market downturns, reflecting a philosophy of holding stocks for multiple years. A key element was the selection of companies with strong fundamentals, including those with legal monopolies, high-growth potential, and capable of generating significant cost savings. Notably, the portfolio included six companies: Pfizer, PubMatic, Sirius XM Holdings, Intel, BioMarin Pharmaceutical, and Fastly.

Individual Stock Holdings

• Pfizer (PFE): The investor recognized the undervalued nature of Pfizer, stemming from the success of its COVID-19 vaccine and oral therapy. Despite a recent sales downturn, Pfizer’s oncology segment and potential cost savings offered substantial growth prospects. The purchase was made at a cost basis of $23.47 per share, just above the June 2 closing price.

• PubMatic (PUBM): A significant investment was made in PubMatic, an adtech company positioned to benefit from the shift towards digital advertising. The investor doubled their stake in the company, acquiring shares at $9.29. This purchase was predicated on PubMatic’s ability to support publishers transitioning from traditional advertising channels.

• Sirius XM Holdings (SIRI): The satellite-radio operator was included due to its legal monopoly and unique revenue structure, primarily based on subscriptions, making it less vulnerable to economic downturns. The investment was made at $19.28 per share, reflecting the company’s stable revenue model.

• Intel (INTC): The portfolio retained Intel as a long-term holding, anticipating a turnaround enabled by late entry into the artificial intelligence (AI) market. Despite trailing competitors, Intel’s established brand and central processing unit (CPU) market leadership offered potential for growth. The stock was purchased at $18.56.

• BioMarin Pharmaceutical (BMRN): This specialty drugmaker was acquired at a cost of $56.01, driven by its focus on rare diseases, which often face limited competition and high pricing power. The investment was supported by BioMarin’s promising Voxzogo drug for achondroplasia and its target sales for 2027.

• Fastly (FSLY): The investor added to their Fastly position, recognizing the growing demand for edge cloud computing services as businesses shifted data and customer information to the cloud. The stock was purchased at $5.08, underpinned by Fastly’s revenue retention rate and growing backlog.

Overall Portfolio Positioning

The selection of these six stocks illustrates a strategic approach to investing during periods of market volatility, prioritizing companies with durable competitive advantages and substantial long-term growth potential. The portfolio’s diversification, combined with a disciplined investment philosophy, aimed to navigate market fluctuations and generate attractive returns over the long term.